Oncology

The FDA has granted priority review for an NDA for the hypoxia-inducible factor-2 alpha inhibitor MK-6482 for the potential treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma that does not require immediate surgery.

A panel of experts in the management of NETs discuss the role of peptide receptor radionuclide therapy for NETs.

A viewpoint perspective from 3 experts endorsed the requirement for a patient and their physician to engage in a shared discussion of benefits and harms before proceeding with a low-dose spiral computed tomography (LDCT) scan in order to prevent lung cancer death.

The FDA announced that it will hold a public meeting of the Oncologic Drugs Advisory Committee from April 27 to 29 to address the indications granted accelerated approval for 6 therapies.

Bristol Myers Squibb and bluebird bio are seeking FDA approval for ide-cel as a standard therapy for relapsed myeloma, with a decision expected by the end of March.

The FDA has granted a fast track designation to poziotinib for use in previously treated non-small cell lung cancer patients with HER2 exon 20 mutations.

Dwight Kloth, PharmD, FCCP, BCOP, director of pharmacy at Fox Chase Cancer Center, discusses the role of the oncology pharmacist in the cancer care continuum, and how this role has been impacted by the COVID-19 pandemic.

Cecilia Lau, RPh, BCOP, APh, and Daneng Li, MD, discuss the management of stomatitis caused by everolimus when used for NETs.

Megan May, PharmD, BCOP, and Daneng Li, MD, discuss the availability of home-injection programs for patients with NETs, especially during the coronavirus pandemic.

The panel of experts in the management of NETs review the indications and safety data of the somatostatin analogues.

Megan May, PharmD, BCOP, and Daneng Li, MD, review the efficacy and the pivotal trials for the somatostatin analogues in the treatment of NETs.

Experts in the management of NETs discuss how the treatment landscape has evolved.

Megan May, PharmD, BCOP, and Daneng Li, MD, discuss when patients with NETs should be considered for active surveillance vs treatment.

A panel of experts in neuroendocrine tumors provide a definition of the disease and the diagnosis methods.

Pipeline drugs, expanding pharmacist roles, and a focus on COVID-19 vaccination are trends to watch for in 2021.

This model focuses sharply on orphan diseases to better address the patient experience, outcomes, and requirements of each study.

The investigators performed a retrospective review of 215 patients age 65 years and older with TNBC or HER2+ breast cancer who underwent mastectomy from 2005 to 2020 at a single institution.

Investigators are set to begin testing sulfasalazine and auronofin, which are FDA-approved to treat rheumatoid arthritis, in cancer cell models.

Research over the past decade has shown that PV can be associated with a reduction in survival compared with age- and gender-matched population controls.

The FDA has approved a supplemental new drug application for lorlatinib (Lorbrena) to expand the indication to include the frontline treatment of patients with ALK-positive non–small cell lung cancer.

There are specific treatment options patients may qualify for depending on the cytogenetic or molecular abnormality detected.

Many rural areas identify with many barriers in their community, such as transportation, technology access, human factors, and the design of the health care model.

Recent data have shown alarmingly low rates of human papillomavirus (HPV) vaccine completion among children between 10 and 13 years of age.

One way of approaching the process of allowing patients to self-report their symptoms is through an electronic patient-reported outcomes (ePRO) system.

Although there have been many challenges and concerns during the pandemic, experts said there are also lessons to be learned and implemented once the pandemic is over.

The CDC recommends that patients with cancer and COVID-19 have a conversation with their health care provider or care team to discuss the individual level of risk based on the patient’s current condition, treatment, and the level of transmission within their community.

A supplemental new drug application has been submitted to the FDA for ivosidenib tablets (Tibsovo) as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.

This activity is supported by educational grants from Seagen Inc., Daiichi Sankyo, and AstraZeneca.